MHRA

With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants

Using the Integrated Scientific Advice service from the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE).

Extra information for the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) Integrated Scientific Advice (ISA) service.

Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.

Patients benefit from earlier access to technologies that could improve or save lives, as the MHRA approved 17 per cent more clinical investigations in 2025 compared with 2024, and launches measures to support innovation and growth.

A list of Field Safety Notices: 09-13 February 2026

Norgine Limited is recalling one batch of product as a precautionary measure due to some units containing low amounts of active ingredients.

MHRA launches a consultation on indefinite recognition of CE-marked medical devices  

Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.

This consultation invites views on proposals for recognising CE marked medical devices in Great Britain.

Reporting, investigating and recalling suspected defective medicinal products to the Defective Medicines Report Centre (DMRC).

Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.